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ess: egpachon@hotmailSummary Red cell macrocytosis has been frequently described in hypoxemic
patients with chronic obstructive pulmonary disease (COPD). However, macrocytosis
is not related to hyoxemia. The objective of this study was to determine the
frequency of macrocytosis (defined as mean corpuscular volume (MCV) higher than
94 fl) in stable COPD patients without respiratory insufficiency, and to analyze the
possible relationship between its presence and clinical and functional parameters.
Fifty-eight consecutive patients with COPD, and without other significant comorbid
conditions, were included in the study. Macrocytosis was present in 17 of the 58
stable COPD patients (29%). The differences between patients with and without
macrocytosis were not statistically significant, except for MCV. In the subgroup of 36
ex-smoker COPD patients, macrocytosis was present in nine patients (25%). In this
subgroup, MCV significantly correlated with dyspnea (r ¼ 0.36, P ¼ 0.03) and forced
expiratory volume in 1 s (FEV1) (r ¼ 0.35, P ¼ 0.03). We conclude that macro-
cytosis is a frequent finding in stable non-hypoxemic COPD patients, and that in ex-
smoker patients the degree of macrocytosis is associated with a worse clinical
situation in terms of dyspnea and FEV1.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Several studies confirm the relatively high fre-
quency of red cell macrocytosis in patients withElsevier Ltd. All rights reserv
679815;
.com (E. Garcia-Pachon).chronic obstructive pulmonary disease (COPD).1–4
This macrocytosis has been generally considered
to be secondary to hypoxemia. However, this
assumption has not been demonstrated since no
significant correlation has been found between
macrocytosis and hypoxemia.4 For this reason, we
tried to determine the frequency of macrocytosis in
stable patients with COPD without respiratoryed.
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ship between its presence and clinical and func-
tional parameters.Methods
Fifty-eight consecutive patients with COPD, diag-
nosed according to international recommenda-
tions,5 (post-bronchodilator forced expiratory
volume in 1 s [FEV1] to forced vital capacity
[FVC]o0.70), and with oxygen saturation higher
than 90%, attending the outpatient pulmonary
clinic were included. Patients were in clinically
stable condition (at least one month without
exacerbation), and without other significant co-
morbid conditions (renal or hepatic disease, con-
gestive heart failure, diabetes mellitus or thyroid
dysfunction), or use of systemic corticosteroids,
diuretics or cytotoxic drugs. The daily alcohol
intake was in all cases lower than 40 g/day, and
no other data suggesting alcohol abuse were
observed. Patients with anemia (hemoglobin lower
than 13 g/dl) were not included. All patients were
smokers or ex-smokers.
Data for hematologic variables were obtained in
a routine blood sample test, and hematocrit,
hemoglobin and mean corpuscular volume (MCV)
were recorded. The following data were also
recorded: smoking history (pack-years); body mass
index (BMI); dyspnea score during normal activities,
as measured on the modified Medical Research
Council scale,6 which ranges from 0 (no dyspnea) to
4 (dyspnea with minimum activities); number of
exacerbations of COPD during the last 12 monthsTable 1 Total patients’ characteristics (n ¼ 58).
VC
Subjects (number (%)) 41
Male/female 39
Age (years) 67
Ex-smokers (n ¼ 36) 27
Smoking history (pack-years) 62
Body mass index (kgm2) 29
FVC (% predicted) 68
FEV1 (% predicted) 51
FEV1/FVC (%) 52
Oxygen saturation (%) 95
Dyspnea (MRC scale) 1.
COPD exacerbations in the previous year 1.
Number of prescribed medicines for COPD 2.
Hemoglobin (g/dl) 14
Mean corpuscular volume (fl) 90
Hematocrit (%) 44
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s;(unscheduled visits to physician, visits to the
emergency room, and hospitalizations); and num-
ber of prescribed medicines to treat the COPD
(short-acting b-agonists, long-acting b-agonists,
anticholinergics, methylxanthines, inhaled corti-
costeroids, mucolytics, diuretics, oxygen). A spiro-
metry was performed (Datospir 120D, Barcelona,
Spain), and post-bronchodilator results were con-
sidered. Spirometic reference values for the Med-
iterranean population were used.7 Oxygen
saturation was measured with a pulse oximeter
sensor (Datospir 120D, Barcelona, Spain).Statistical analysis
Data are presented as mean7standard deviation
(SD) or percentage where indicated. Differences
between patients with and without macrocytosis
(defined as MCV higher than 94 fl) were compared
by unpaired t-test or w2 test where appropriate. To
determine the relationships between variables,
Spearman’s rank correlation test was used. Because
current smoking may alter clinical or hematological
parameters, the group of ex-smokers was analyzed
separately. A P-value less than 0.05 was considered
to be statistically significant.Results
Macrocytosis (defined as MCV higher than 94 fl4) was
present in 17 of the 58 stable COPD patients (29%).
The characteristics of the patients with and with-
out macrocytosis are detailed in Table 1. TheMo94 VCM494 P
(71%) 17 (29%)
/2 16/1
79 6978 NS
(66%) 9 (53%) NS
725 55729 NS
76 2675 NS
719 67717 NS
716 45716 NS
712 48712 NS
72 9472 NS
171.1 1.071.2 NS
7871.95 1.2971.05 NS
871.9 3.272.0 NS
.970.8 14.671.1 NS
73 9873 o0.001
73 4473 NS
ER, emergency room.
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Table 2 Ex-smokers: patient characteristics (n ¼ 36).
VCMo94 VCM494 P
Subjects (number) 27 (75%) 9 (25%)
Male/female 26/1 8/1
Age (years) 6878 6978 NS
Smoking history (pack-years) 59725 57733 NS
Ex-smokers (years) 1079 776 NS
Body mass index (kgm2) 3077 2874 NS
FVC (% predicted) 66719 61715 NS
FEV1 (% predicted) 49720 40717 NS
FEV1/FVC (%) 51712 47714 NS
Oxygen saturation (%) 9572 9472 NS
Dyspnea (MRC scale) 1.071.0 1.271.1 NS
COPD exacerbations in the previous year 2.072.1 1.571.0 NS
Number of prescribed medicines for COPD 3.271.9 3.872.0 NS
Hemoglobin (g/dl) 14.970.8 14.170.9 0.01
Mean corpuscular volume (fl) 9073 9772 o0.001
Hematocrit (%) 4573 4273 0.01
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; ER, emergency room.
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tically significant, except—as expected—for MCV.
In these patients, MCV did not correlate with any of
the clinical or functional parameters. Four patients
(7%), three male and one female, had MCV higher
than or equal to 100 fl. The mean FEV1 of these
patients was 49%715 of the predicted value, the
oxygen saturation 94%71, and the number of
exacerbations 2.070.8; similar to the results of
the group as a whole.
Table 2 shows the characteristics of the 36 ex-
smoker patients (at least 6 months without smok-
ing). In this group, macrocytosis was present in nine
patients (25%). Groups with and without macro-
cytosis significantly differ in MCV, hemoglobin and
hematocrit. In the group of ex-smoker patients,
MCV significantly correlated with dyspnea
(r ¼ 0.36, P ¼ 0.03) and forced expiratory volume
in 1 s (r ¼ 0.35, P ¼ 0.03).
Oxygen saturation did not correlate with MCV in
the total of patients or in the group of ex-smoker
patients.Discussion
This study shows that a significant proportion (29%)
of stable COPD patients without respiratory insuffi-
ciency have macrocytosis. Patients with and with-
out macrocytosis did not differ in terms of clinical
and functional characteristics. Although in this
series most patients had mild macrocytosis, 7% of
patients had MCV values higher than or equal to100 fl. No differences were found between these
patients and the group as a whole. The presence of
macrocytosis in COPD patients has been known for
decades.1–3 However, interest was focused on
hypoxemic patients. Morphometric and analytical
cytologic studies have shown alterations of red
blood cell rigidity,8 and changes of spectrin
cytoskeleton and gycophorin expression.9 The find-
ing of very high MCV in COPD has also been
previously reported in a series of 109 patients with
frank macrocytosis—higher than 105 fl—(excluding
those treated with cytotoxic or immunosuppressing
drugs). After an intensive study, three cases were
considered due to COPD.8 It is well known that MCV
may be high as a consequence of a large variety of
causes.10,11 In our patients we took special care in
excluding those with comorbid conditions asso-
ciated with an elevated MCV, such as alcohol abuse
or use of different drugs that are the main causes of
macrocytosis.11 but also other conditions occasion-
ally associated with macrocytosis.10,11 As was to be
expected in view of previous studies, in our
patients MCV did not correlate with oxygen satura-
tion or with other clinical or functional variables.
However, since active smoking can influence
hematological parameters, we analyzed the data
for ex–smoker patients separately. It is well known
that smoking is associated with increased hemoglo-
bin and MCV.12 Importantly, we found that in the
group of ex-smoker patients MCV correlated with
the degree of dyspnea for usual activities measured
on the MRC scale, and with the FEV1. Both groups
were slightly different in the hemoglobin level that
can, hypothetically, influence the results and we
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of interest in these patients.
Our findings are of interest regarding recent
suggestions on the origin of macrocytosis in COPD.4
Tsantes et al.,4 in hypoxemic patients with COPD,
found macrocytosis in almost half of the 32 patients
included in their study. After investigating the
causes of the abnormal erythrocytic parameters,
they postulated that acute erythropoietic stress
occurring repeatedly may lead to release of waves
of immature large red cells from the marrow.4 In
our study, in patients that are not currently
smokers, MCV does not correlate with the number
of exacerbations in the previous year, but it does
with parameters that effectively define patients
with a worse condition: higher dyspnea and lower
lung function. This finding agrees with the hypoth-
esis proposed by Tsantes et al.4
In conclusion, mild macrocytosis is a frequent
finding in stable patients with COPD and without
respirator insufficiency, and frank macrocytosis is
not a rare characteristic. However, studies with
large samples of COPD patients and including values
of serum vitamin B12 and folate are necessary in
order to achieve a better understanding of this
finding. In ex-smoker patients MCV correlates with
worse clinical and functional parameters support-
ing the hypothesis that macrocytosis is due to acute
erythropoietic stress that may lead to release of
large red cells from the marrow.References
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